Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Large B-Cell Lymphoma

Large B-Cell Lymphoma

19

Pipeline Programs↗

14

Active Trials↗

14

Companies Involved↗

Large B-cell Lymphoma is an emerging landscape with 19 programs across 14 companies. 7 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

49/100

Pipeline Velocity

25/100

Mech. Concentration

22/100

Completion Rate

N/A

Attrition Rate

0/100

Pipeline

Programs by Phase

Preclinical2

Polatuzumab Vedotin

Roche

Sonrotoclax

BeOne Medicines

Phase 13

Vancomycin

Hikma Pharmaceuticals LLC

Pemetrexed Disodium

Eagle Pharmaceuticals, Inc.

Dexamethasone

Aspen Global Incorporated

Phase 27

Fludarabine

Sanofi

Lymphodepleting Chemotherapy

Beijing Biotech

CD70.CAR NK Cells

M.D. Anderson Cancer Center

Rimiducid

Bellicum Pharmaceuticals

Loncastuximab Tesirine

Akero Therapeutics

Phase 37

Cyclophosphamide

Baxter Healthcare Corporation

Doxorubicin

Pfizer

Prednisone

Roxane Laboratories

Golcadomide

Bristol-Myers Squibb

Rituximab

Roche

Approved

No programs

Analysis

Modality Breakdown

63%

Small molecule

12 of 19 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 19 classified programs, each share of the total. Modality classified for 100% of 19 pipeline programs.

Analysis

Trial Status

14

clinical trials

Recruiting8 · 57%

Active, not recruiting3 · 21%

Not yet recruiting3 · 21%

Clinical Trials

Trial Activity

14 trials

A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma

Recruiting·AAllogene Therapeutics·Phase 2·NCT06500273·250 enrolled

Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06045247·40 enrolled

A Phase 2 Trial to Evaluate the Efficacy and Safety of WZTL-002 in Patients With Relapsed or Refractory Large B-cell Lymphoma (ENABLE-2)

Recruiting·MMalaghan Institute of Medical Research·Phase 2·NCT06486051·60 enrolled

A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel , an Autologous, Dual-targeting CD19/CD20 CAR T-Cell Product Candidate, Vs. Investigator's Choice of CD19 CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-Cell Lymphoma in the Second-line Setting

Recruiting·LLyell Immunopharma, Inc.·Phase 3·NCT07188558·400 enrolled

A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05464719·30 enrolled

A Pilot Trial of Bridging Radiation Therapy With Oral Vancomycin for Patients With B-cell Lymphomas Undergoing CAR-T Therapy

Recruiting·AAbramson Cancer Center at Penn Medicine·Phase 1·NCT07478848·14 enrolled

Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07316010·50 enrolled

A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination With Rituximab and Reduced Dose CHOP (R-miniCHOP) in OldEr Adults With Untreated Diffuse Large B-Cell Lymphoma

Recruiting·UUniversität des Saarlandes·Phase 3·NCT05820841·330 enrolled

Phase II Study of Dual Targeting of CD19 and CD20 Antigens Using Sequential CD19-directed CAR-T Cells Followed by Mosunetuzumab or Glofitamab in Relapsed or Refractory Diffuse Large B-cell or Transformed Follicular Lymphomas

Active, not recruiting·AAbramson Cancer Center at Penn Medicine·Phase 2·NCT04889716·23 enrolled

A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

Active, not recruiting· Roche logo

Roche·Phase 3·NCT06047080·1,130 enrolled

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT06356129·850 enrolled

Phase I Pilot Trial of Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas

Not yet recruiting·—·Phase 1·NCT07608731·18 enrolled

Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07164469·100 enrolled

A Single-Arm, Prospective Study of Pola-R-CHP Plus Sonrotoclax in Patients With Previously Untreated Large B-Cell Lymphoma (LBCL) With High BCL2 Expression / Double-Hit Lymphoma

Not yet recruiting·RRuijin Hospital·Preclinical·NCT07638787·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)